| 查看: 667 | 回复: 8 | |||
| 当前主题已经存档。 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
caifuxia银虫 (小有名气)
|
[交流]
【原创】医药创造财富
|
||
|
医药创造财富：90379370 诚邀医药精英谈医论药，煮酒论英雄。分享医药研 究立项、动态、经验、资料等，分享独到产品的市场分析；分享招商的经验与客户资料。本群将不定期发布新产品的立项资料、新药研发资料、市场分析资料、招商产品分析资料、客户资料。 精英海聚 同心戮力 互惠共赢 |
回复此楼» 猜你喜欢
硅胶柱可以用纯二氯甲烷洗脱吗
已经有18人回复
-
求购时间长一些的硝酸钍
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有148人回复
-
脑梗怎么治疗
已经有3人回复
-
脑梗怎么治疗
已经有0人回复
-
生物组织中有目标分析物，专属性怎么做
已经有0人回复
» 本主题相关商家推荐: (我也要在这里推广)
caifuxia
银虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 2661.6
- 帖子: 67
- 在线: 549.2小时
- 虫号: 25443
- 注册: 2003-10-10
- 性别: GG
- 专业: 合成药物化学
立项发布
|
(2009-07-02 12:24:20) 财富(751899926) Pharmaprojects Accession No: 1852 Main Details Drug Name World Status Pharma Status pirmenol Launched Fully Launched CI-845 Pimenol pirmavar Latest Change Updated On By Latest Change 6 Oct 2005 IL Dainippon Sumitomo Pharma merger reported Company Status Data Originator Country Development Stage Pfizer USA Launched Activity Data Therapy Description Code Status Antiarrhythmic C1B Launched Pharmacology Description Code Sodium channel antagonist CHA-NA- Therapy Code Pharmacology Code C1B CHA-NA- Route of Administration Route of Administration Code Alimentary, po A-PO Indication Status Tachycardia, supraventricular Launched Chemical Data Origin of Material Code Description CH-SY Chemical, synthetic CAS Registry Number Molecular Weight Molecular Formula 61477-94-9 68252-19-7 338.50 C22H30N2O Chemical Name (2-Pyridinemethanol, alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.alpha.phenyl-, cis-(+)- [CAS] Structure Patent Data Country Number Priority Country Priority Date US 4112103 US 15 April 1976 Country Data Country Name Status Year Launched Licensing Op. Argentina - No Australia - No Austria - No Belgium - No Brazil - No Canada - No Chile - No China - No Colombia - No Denmark - No Finland - No France - No Germany - No Greece - No Hong Kong - No India - No Ireland - No Israel - No Italy - No Japan Launched 1995 No Luxembourg - No Malaysia - No Mexico - No Netherlands - No New Zealand - No Norway - No Peru - No Philippines - No Portugal - No Russian Federation - No South Africa - No South Korea - No Spain - No Sweden - No Switzerland - No Thailand - No Turkey - No UK - No USA - No Venezuela - No Major Events Event Date Act/Est Event Details 15 May 1997 Est Licences Discontinued Dainippon 15 Mar 1996 Est New Licensees Dainippon 15 Mar 1996 Est First Launches Japan 15 Sep 1992 Est Registration Submissions Japan Ratings Novelty Market Size Speed Total Established Strategy (2) US$ 501-2000 million (2) Not available (0) Not available Detailed Information Pirmenol is a long-acting class Ia antiarrhythmic, developed by Parke-Davis (Pfizer). It has similar antiarrhythmic efficacy to procainamide (qv) (Pacing Clin Electrophysiol, 1988, 11, 308). Marketing It is launched in Japan (1995) (Scrip, 1992, 1741, 23; Company communications, Parke-Davis, Dec 1993 & Jan 1996). It was previously developed with Dainippon (now Dainippon Sumitomo Pharma) (Company communication, Warner-Lambert, Jan 1996), but is no longer under joint-development (Company communication, Dainippon, Feb 1997). Clinical In 17 patients with frequent ventricular ectopic depolarizations, 100-200mg/day pirmenol prolonged the QRS and QT intervals without affecting the JT, QTc and JTc intervals. All pirmenol recipients achieved 75% suppression of arrhythmias (Clin Cardiol, 1991, 14, 25). In 20 patients with paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation, 200mg pirmenol po significantly increased heart rate and total systemic resistance, and reduced the stroke volume index. It restored sinus rhythm during tachyarrhythmia in 4/7 patients with PSVT and 4/9 patients with paroxysmal atrial fibrillation. It was well tolerated (J Cardiovasc Pharmacol, 1996, 27, 556). Updated by PA on 27/5/1998. Additional Clinical Information Phase II In patients with supraventricular tachycardia, 200mg po inhibited induction of tachycardia in 5/11 at 60min post-dose and in 7/11 at 120min; no side-effects were seen (3rd Cardiovasc Pharmacother Int Symp (Kyoto), 1989, Abs P575, 0). 2008 1′7 29 -￥ Copyright Informa UK Ltd 2008 |
7楼2009-07-02 12:28:22
caifuxia
银虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 2661.6
- 帖子: 67
- 在线: 549.2小时
- 虫号: 25443
- 注册: 2003-10-10
- 性别: GG
- 专业: 合成药物化学
|
心血管 心率失常、强心药也许是个被忽略的领域 输液 开发目前国内空白的电解质 干眼症、眼科用药 这类药品的市场看看福瑞达、珍视明、仁和的效益就知道 眼科手术冲洗液目前还没有竞争品种 肝病辅助用药 肝病的辅助用药品种不多，但销量都不错 扁桃体发炎后的口腔炎用药 目前市场上还没有针对这种病的药物，而且小孩高烧后均会出现这种情况。手术插管也可以使用。手术用药是每个经销商的最爱。 呕吐栓剂 小孩生病常出现呕吐，但市场上还没有针对这种病的药物 肿瘤药 他滨类抗白血病药 手术用肌松药 一个容易被忽略的领域，因为药品研究的人员少有在药房的工作过。也许只有我能看到这个品种 激素类药物 看看可的松的销量就知道市场有多大 磷酸化物 增加水溶解性，多个这类化合物立项 肿瘤辅助用药、抗生素 工艺难度大考虑授权引进（license-in），类似香菇多糖注射剂 电解质注射液 类似复合磷酸氢钾注射液。目前只有天津氨基酸厂有类似品种 便秘栓 看看开塞露销量就知道市场有多大 其他 涉及抗高血压、抗真菌外用药、止吐、脑外科术后等热点品种 |
2楼2009-06-28 17:55:51
3楼2009-06-28 19:09:51
gene112
金虫 (文坛精英)
- 应助: 3 (幼儿园)
- 贵宾: 0.04
- 金币: 1459.9
- 散金: 3800
- 红花: 23
- 沙发: 12
- 帖子: 12577
- 在线: 845小时
- 虫号: 751817
- 注册: 2009-04-18
- 性别: GG
- 专业: 神经变性、再生及相关疾病
4楼2009-06-28 19:35:50
